LXEO

Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for cardiovascular, central nervous system, and ocular diseases. The company utilizes adeno-associated virus (AAV) delivery platforms to address genetic disorders with significant unmet medical needs. Lexeo focuses on one-time therapeutic interventions that could provide long-term benefits to patients with inherited conditions.